-
07/16/08Jennerex Publishes Clinical Trial Data with Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated
Hepatitis B Virus - 06/02/08Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
- 05/21/08Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
- 11/08/07Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
- 10/23/07Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
- 10/17/06Jennerex and Green Cross Enter Agreement to Develop and Commercialize JX-594 In South Korea